New drug duo aims to control tough blood cancer

NCT ID NCT03478514

Ongoing Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two oral drugs, palbociclib and ibrutinib, can help control mantle cell lymphoma in patients whose cancer has returned or worsened after at least one prior treatment. The main goal is to see how long the combination can keep the cancer from progressing. About 39 patients will take both pills daily in repeating 28-day cycles until the cancer grows, side effects become too severe, or they choose to stop.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope National Medical Center

Duarte, California, 91010, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical University of South Carolina - Hollings Cancer Center

Charleston, South Carolina, 29425, United States
Ohio State University

Columbus, Ohio, 43210, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
St. Joseph Mercy Hospital Cancer Care Center

Ypsilanti, Michigan, 48197, United States
University of Maryland, Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
Weill Cornell Medical College

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

B-CELL LYMPHOMA MANTLE CELL LYMPHOMA